A detailed history of Vanguard Personalized Indexing Management, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Vanguard Personalized Indexing Management, LLC holds 35,862 shares of EXEL stock, worth $1.26 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
35,862
Previous 31,549 13.67%
Holding current value
$1.26 Million
Previous $708,000 31.36%
% of portfolio
0.02%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$21.96 - $27.6 $94,713 - $119,038
4,313 Added 13.67%
35,862 $930,000
Q2 2024

Aug 12, 2024

SELL
$20.34 - $23.73 $7,749 - $9,041
-381 Reduced 1.19%
31,549 $708,000
Q1 2024

May 09, 2024

SELL
$20.17 - $23.93 $157,467 - $186,821
-7,807 Reduced 19.65%
31,930 $757,000
Q4 2023

Feb 07, 2024

BUY
$19.25 - $24.13 $71,205 - $89,256
3,699 Added 10.26%
39,737 $953,000
Q3 2023

Nov 08, 2023

BUY
$19.04 - $22.74 $1,618 - $1,932
85 Added 0.24%
36,038 $787,000
Q2 2023

Jul 28, 2023

BUY
$18.17 - $20.48 $20,059 - $22,609
1,104 Added 3.17%
35,953 $687,000
Q1 2023

May 10, 2023

BUY
$16.3 - $19.41 $145,885 - $173,719
8,950 Added 34.56%
34,849 $676,000
Q4 2022

Feb 10, 2023

BUY
$14.96 - $17.39 $8,811 - $10,242
589 Added 2.33%
25,899 $415,000
Q3 2022

Nov 14, 2022

SELL
$15.68 - $22.27 $74,276 - $105,492
-4,737 Reduced 15.77%
25,310 $397,000
Q2 2022

Aug 09, 2022

BUY
$17.44 - $23.16 $352,043 - $467,507
20,186 Added 204.71%
30,047 $626,000
Q1 2022

May 16, 2022

BUY
$17.03 - $22.67 $167,932 - $223,548
9,861 New
9,861 $224,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.3B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Vanguard Personalized Indexing Management, LLC Portfolio

Follow Vanguard Personalized Indexing Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Personalized Indexing Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Personalized Indexing Management, LLC with notifications on news.